CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $372,000 | +4.5% | 5,700 | -2.6% | 0.02% | +4.5% |
Q2 2022 | $356,000 | -3.3% | 5,850 | -0.2% | 0.02% | +46.7% |
Q1 2022 | $368,000 | -22.7% | 5,860 | -6.6% | 0.02% | -11.8% |
Q4 2021 | $476,000 | -41.5% | 6,275 | -13.7% | 0.02% | -46.9% |
Q3 2021 | $814,000 | -58.2% | 7,275 | -39.5% | 0.03% | -57.9% |
Q2 2021 | $1,947,000 | +114.4% | 12,025 | +61.4% | 0.08% | +100.0% |
Q1 2021 | $908,000 | -9.5% | 7,450 | +13.7% | 0.04% | -15.6% |
Q4 2020 | $1,003,000 | +110.3% | 6,550 | +14.9% | 0.04% | +87.5% |
Q3 2020 | $477,000 | +8.2% | 5,700 | -5.0% | 0.02% | -4.0% |
Q2 2020 | $441,000 | -87.3% | 6,000 | -92.7% | 0.02% | -91.5% |
Q1 2020 | $3,462,000 | +440.9% | 81,642 | +677.5% | 0.30% | +821.9% |
Q4 2019 | $640,000 | +119.9% | 10,500 | +47.9% | 0.03% | +100.0% |
Q3 2019 | $291,000 | -17.6% | 7,100 | -5.3% | 0.02% | -15.8% |
Q2 2019 | $353,000 | – | 7,500 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |